Medigene AG to present Phase I clinical data for MDG1011 with poster presentation at EBMT 2023 Annual Meeting
April 11, 2023 10:45 ET
|
Medigene AG
Martinsried/Munich, April 11, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene AG Presents Systematic and Sequential, End-To-End Platform Approach to Optimize TCR-T Therapy Development
April 04, 2023 10:00 ET
|
Medigene AG
Martinsried/Munich, April 04, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard) is an early-stage immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene enters Cooperative Research and Development Agreement with the National Cancer Institute to evaluate the use of Medigene’s proprietary T cell receptors in novel cell constructs
April 03, 2023 12:45 ET
|
Medigene AG
Martinsried/Munich, April 3, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Reports Full-Year 2022 Financial Results and Provides Corporate Update
March 29, 2023 01:30 ET
|
Medigene AG
Continued progress in 2022 with corporate strategy update, end-to-end platform innovation, pipeline expansion, and acceleration of lead candidate developmentPartnering momentum continues with a $3...
Medigene AG to present at the 4th TCR-based Therapies for Solid Tumors Summit in Boston
March 28, 2023 11:00 ET
|
Medigene AG
Martinsried/Munich, March 28, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Announces Appointment of Dr. Kirsty Crame, MD, as Head of Clinical Research & Development
March 20, 2023 06:00 ET
|
Medigene AG
Martinsried/Munich, March 20, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene to present first pre-clinical data for MDG1015 with poster presentation at AACR 2023 Annual Meeting
March 16, 2023 05:00 ET
|
Medigene AG
Martinsried/Munich, March 16, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG to report full year 2022 financial results on March 29, 2023
March 15, 2023 11:47 ET
|
Medigene AG
Martinsried/Munich, March 15, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell...
BioNTech und Medigene gehen globale Kollaboration zur Entwicklung von T-Zell-Rezeptor-Immuntherapien gegen Krebs ein
February 21, 2022 13:25 ET
|
BioNTech SE
Die Zusammenarbeit kombiniert BioNTechs plattformübergreifende Immuntherapie-Kompetenzen mit Medigenes Entdeckungsplattform zur Identifizierung neuer T-Zell-Rezeptoren (TCRs), um innovative...
BioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer
February 21, 2022 13:25 ET
|
BioNTech SE
Collaboration leverages BioNTech’s multi-platform immunotherapy capabilities and Medigene’s T cell receptor (TCR) discovery platform to discover and develop innovative TCR immunotherapies against...